Posted by Brian Bell, University of Oxford and John Van Reenen, MIT Sloan School of Management, on Sunday, September 4, 2016 Editor's Note: Brian Bell is Associate Professor of Economics at University of Oxford and John Van Reenen is a Professor of Applied Economics at the MIT Sloan School
Merck & Co., Inc. (NYSE:MRK) announced Monday that it has entered into a multi-year collaboration agreement with NGM Biopharmaceuticals Inc., a privately held biotechnology company, to research, develop, as well as commercialize innovative biologic therapies ranging across a wide array of therapeutics.
Merck & Co., Inc. (NYSE:MRK), the second-largest US drug maker, has announced an agreement with the Medicines Patent Pool (MPP) for its HIV drug, raltegravir, in its efforts to expedite the process of developing low-priced pediatric formulations for developing countries.
KOLKATA: The core idea behind corporate governance reforms in India is the promotion of long term sustainability of business enterprises, a top Sebi official said today. Accountancy, independence, transparency and honesty are the prime drivers of the corporate governance regime in the country, said V S Sundaresan, chief general manager of Sebi. He was speaking at a conference titled 'Corporate Governance: New dimensions of Board Practices and Responsibilities', organised jointly by Indian Chamber of Commerce and NFCG here.
Merck & Co., Inc. (NYSE:MRK) ended up paying $8.4 billion to acquire Cubist Pharmaceuticals Inc (NASDAQ:CBST), a 37% premium over Cubist’s closing stock price of $74.36 Friday; however, by Monday morning, this amount looked at least $2 billion too high as Cubist lost a key patent-infringement case pertaining to its blockbuster drug, Cubicin.
Editor’s Note: The following post comes to us from Klaus J. Hopt, a professor and director (emeritus) at the Max-Planck-Institute for Comparative and International Private Law, in Hamburg and was advisor inter alia for the European Commission, the German legislator and the Ministries of Finance and of Justice.
Banks are special, so is corporate governance of banks.
Grant Sawiak is a partner at Fogler Rubinoff and a former staffer at the TSX who recently successfully advised a group of dissidents at Continental Precious Minerals Inc., a small mining company with an operation in Sweden.
Sawiak’s involvement in Continental’s proxy battle – which now has a new team of directors that doesn’t include the chief executive – gave him a first-hand look at corporate governance in the junior mining sector, a sector that’s home to thousands of companies which, in market cap terms, is typical of much of corporate Canada.
Chemistfrog submits:Ariad Pharmaceuticals (NASDAQ: ARIA) captured Merck’s (NYSE: MRK) attention enough with its cancer drug, ridaforolimus, in July 2007 to forge a partnership to help Ariad through several clinical trials for multiple cancer indications.